ECRIN is a distributed research infrastructure – a distinct organisation that connects research facilities at multiple sites in countries across Europe and provides services for top-level clinical research. This infrastructure creates added value through greater access to expertise and patients, increasing the reach, diversity, and quality of results of clinical trials.
Based in Paris, we work with European Correspondents across Europe, national networks of clinical trial units (CTUs), as well as numerous European and international stakeholders involved in clinical research. Learn how we work with our Member and Observer Countries below.
On November 29th, 2013, ECRIN was officially awarded the status of European Research Infrastructure Consortium (ERIC) by the European Commission. This is a legal status recognised in all EU member states, designed to facilitate the establishment and operation of research infrastructures of European interest.
ECRIN Statutes and Internal Rules of Procedure
- View the ECRIN statutes, language: BG CS DA DE EL EN ES ET FI FR HR HU IT LT LV MT NL PL PT RO SK SL SV
- View the consolidated ECRIN statues (EN only) [updated 27 February 2017]
- View Annex II of the ECRIN statutes, List of Members and Observers (EN only) [updated 11 April 2016]
- View the ECRIN internal rules of procedure [updated 20 February 2017]
A European Strategy Forum on Research Infrastructures (ESFRI) Biological and Medical Sciences Research Infrastructure (BMS RI)
In 2006, ECRIN was listed on the European Strategy Forum on Research Infrastructures (ESFRI) roadmap. ESFRI is a strategic instrument developed by the European Commission to focus on optimal use and development of research infrastructures through strategic policymaking and multilateral initiatives. ECRIN is one of 12 ESFRI Biological and Medical Sciences Research Infrastructures (BMS RIs).
The BMS RIs are currently collaborating on the Horizon 2020-funded CORBEL project, for example, to establish shared services for the biomedical research community.
In addition to ECRIN, the BMS RIs are the following:
- EATRIS (translational research)
- EuroBioImaging (cellular and medical imaging)
- ELIXIR (bioinformatics)
- BBMRI (biobanks)
- INSTRUCT (structural biology)
- INFRAFRONTIER (mouse models)
- ISBE (systems biology)
- ERINHA (high-security laboratories)
- MIRRI (microbial collections)
- EMBRC (marine biology)
- EU-OPENSCREEN (chemical libraries and screening)
Members and Observers
To date, ECRIN has seven full Member Countries (France, Germany, Hungary, Italy, Norway, Portugal and Spain) and two Observer Countries (Czech Republic and Switzerland). Member Countries have access to the full range of ECRIN services and collaboration opportunities. Observer status, which lasts for a maximum of three years, grants similar support.
Collaboration with countries is achieved through ECRIN's unique organisation involving the Paris-based Core Team, the European Correspondents based in each Member or Observer Country, and the national Scientific Partners (usually a network of clinical research units, CTUs). Click below to find out about specific roles and responsibilities.
ECRIN is funded by the contributions of its Member and Observer Countries. These funds are primarily dedicated to supporting the organisation and developing its core competencies to enable the provision of operational support to multinational trials.
Country funding does not cover costs incurred by specific projects aimed at developing new tools and procedures, or multinational clinical trials where ECRIN provides trial management services. These projects are funded by grants from European funding bodies (e.g., Horizon 2020, Innovative Medicines Initiative 2) and services provided to industry sponsors, for example.